Shares of Ikena Oncology, Inc. (NASDAQ:IKNA - Get Free Report) were up 1.5% during trading on Tuesday . The company traded as high as $1.42 and last traded at $1.37. Approximately 59,559 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 115,369 shares. The stock had previously closed at $1.35.
Ikena Oncology Trading Down 0.7%
The company has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $1.34.
Ikena Oncology (NASDAQ:IKNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.03. On average, equities analysts anticipate that Ikena Oncology, Inc. will post -0.91 earnings per share for the current fiscal year.
Institutional Trading of Ikena Oncology
Institutional investors and hedge funds have recently made changes to their positions in the business. Gilead Sciences Inc. acquired a new position in shares of Ikena Oncology in the 4th quarter valued at $3,294,000. Aldebaran Capital LLC acquired a new position in shares of Ikena Oncology in the 1st quarter valued at $317,000. JPMorgan Chase & Co. lifted its stake in shares of Ikena Oncology by 18,244.1% in the 4th quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company's stock valued at $255,000 after purchasing an additional 154,892 shares during the period. BML Capital Management LLC lifted its stake in shares of Ikena Oncology by 3.5% in the 1st quarter. BML Capital Management LLC now owns 3,710,803 shares of the company's stock valued at $4,750,000 after purchasing an additional 124,937 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Ikena Oncology by 21.0% in the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company's stock valued at $538,000 after purchasing an additional 56,936 shares during the period. Institutional investors own 75.00% of the company's stock.
About Ikena Oncology
(
Get Free Report)
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Further Reading
Before you consider Ikena Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ikena Oncology wasn't on the list.
While Ikena Oncology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
